OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research note released on Friday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Up 8.2 %

Shares of OPGN opened at $1.81 on Friday. The stock’s 50 day moving average is $1.89 and its two-hundred day moving average is $2.81. OpGen has a twelve month low of $1.49 and a twelve month high of $9.90.

OpGen (NASDAQ:OPGN) last posted its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The company had revenue of $0.03 million during the quarter.

Institutional Trading of OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp purchased a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to its most recent filing with the SEC. The firm purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen at the end of the most recent quarter. 2.68% of the stock is owned by institutional investors and hedge funds.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.